Madrigal Pharmaceuticals

Traded on the St. Petersburg Stock Exchange
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pursuing novel therapeutics of cardio-metabolic and fatty liver diseases.
Madrigal Pharmaceuticals stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Madrigal Pharmaceuticals balance sheet

Report period2018 2019 2020 2021 2022 Q1 23
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Madrigal Pharmaceuticals cash flows

Report period2018 2019 2020 2021 2022 Q1 23 TTM
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
Adjusted Earnings
Funds From Operations
Adjusted FFO
Distributable Cash Flow
Adjusted DCF
EBITDA
Adjusted EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Madrigal Pharmaceuticals multipliers

Report period2018 2019 2020 2021 2022 Q1 23 TTM
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Madrigal Pharmaceuticals profitability

Report period2018 2019 2020 2021 2022 Q1 23 TTM
ROA
ROE
ROS
Madrigal Pharmaceuticals assets
Madrigal Pharmaceuticals cash flows

Madrigal Pharmaceuticals shares

TickerNameTypeNominal valueISINPrice
MDGL:USMadrigal Pharmaceuticals, Inc.Common share-US5588681057$215.6
Madrigal Pharmaceuticals news
09.05.2022
Madrigal Pharmaceuticals' GAAP loss for 3 months of 2022 was $57.518 million, up 9.5% from $52.546 million in the previous year.
Source: {source} pictogram ir.madrigalpharma.com
Pictogram next
24.02.2022
Madrigal Pharmaceuticals' GAAP loss for 2021 was $241.846 million, up 19.6% from $202.244 million in the previous year.
Source: {source} pictogram ir.madrigalpharma.com
Pictogram next
04.11.2021
Madrigal Pharmaceuticals' GAAP loss for 9M 2021 was $177.297 million, up 23.9% from $143.121 million in the prior year.
Source: {source} pictogram ir.madrigalpharma.com
Pictogram next
05.08.2021
Madrigal Pharmaceuticals' GAAP loss for six months of 2021 was $114.197 million, up 34.1% from $85.158 million in the prior year.
Source: {source} pictogram ir.madrigalpharma.com
Pictogram next
All Madrigal Pharmaceuticals news
General information
Company nameMadrigal Pharmaceuticals
Tags#pharmacy
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business address200 BARR HARBOR DRIVE, SUITE 400 WEST CONSHOHOCKEN PA 19428 404-380-9263
Mailing address200 BARR HARBOR DRIVE, SUITE 400 WEST CONSHOHOCKEN PA 19428
Websitewww.madrigalpharma.com